Acumen (NASDAQ: ABOS) insider files to sell 895 shares

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider plans a small stock sale. A Form 144 notice reports an intended sale of 895 shares of Acumen Pharmaceuticals common stock through Merrill Lynch on or about 01/22/2026, with an aggregate market value of $1,628.90. The shares trade on the NASDAQ, where 60,573,425 common shares were outstanding at the time of the notice.

The 895 shares to be sold came from the vesting of a restricted stock unit award on 01/17/2026, granted under the company’s equity compensation plan. The filer, identified as Eric Siemers, also sold 4,000, 6,834, and 2,331 shares of Acumen common stock on 01/05/2026, 01/06/2026, and 01/21/2026, for gross proceeds of $7,834.80, $13,442.82, and $4,203.85, respectively.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	895	1628.90	60573425	01/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/17/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			895	01/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Siemers 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7834.80
Eric Siemers 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	6834	13442.82
Eric Siemers 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/21/2026	2331	4203.85

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Acumen Pharmaceuticals (ABOS) disclose?

The Form 144 notice discloses an insider’s intent to sell 895 shares of Acumen Pharmaceuticals common stock, with an aggregate market value of $1,628.90, on or about 01/22/2026 through Merrill Lynch on the NASDAQ market.

Who is selling Acumen Pharmaceuticals (ABOS) shares and how many?

Eric Siemers is the person for whose account the securities are to be sold. The notice covers a proposed sale of 895 shares of Acumen Pharmaceuticals common stock.

How were the 895 Acumen Pharmaceuticals (ABOS) shares being sold acquired?

The 895 shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of Acumen Pharmaceuticals’ equity compensation plan.

What recent Acumen Pharmaceuticals (ABOS) stock sales has the filer made?

Over the prior three months, Eric Siemers sold Acumen common stock in three transactions: 4,000 shares on 01/05/2026 for $7,834.80, 6,834 shares on 01/06/2026 for $13,442.82, and 2,331 shares on 01/21/2026 for $4,203.85.

On which exchange are Acumen Pharmaceuticals (ABOS) shares listed and how many shares are outstanding?

Acumen Pharmaceuticals common stock is listed on the NASDAQ. The notice states that 60,573,425 common shares were outstanding at the time the Form 144 information was prepared.

Which broker is handling the planned Acumen Pharmaceuticals (ABOS) share sale?

The proposed sale of 895 shares of Acumen Pharmaceuticals common stock is to be executed through Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281.